英文名稱 | Anti-Human PD-1xCTLA-4 Bispecific Antibody(Cadonilimab) |
---|---|
中文名稱 | 卡度尼利單抗 |
CAS號(hào) | 2394841-59-7 |
儲(chǔ)存條件 | -80°C for one-year storage. Avoid repeated freeze-thaw. |
規(guī)格 | 庫存 | 目錄價(jià) | 會(huì)員專享價(jià) | 數(shù)量 | |
---|---|---|---|---|---|
暫無牌價(jià)信息,您可以發(fā)送詢價(jià),我們會(huì)盡快給你回復(fù)。 |
英文名稱 | Anti-Human PD-1xCTLA-4 Bispecific Antibody(Cadonilimab) |
---|---|
中文名稱 | 卡度尼利單抗 |
CAS號(hào) | 2394841-59-7 |
儲(chǔ)存條件 | -80°C for one-year storage. Avoid repeated freeze-thaw. |
Cadonilimab is a pioneering bispecific antibody targeting PD-1 and CTLA-4,it blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).
Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice.
PMID: 38677243 DOI: 10.1016/j.biopha.2024.116669
PMID: 37600791 PMCID: PMC10435079 DOI: 10.3389/fimmu.2023.1188523
PMID: 35030985 PMCID: PMC8765076 DOI: 10.1080/19420862.2021.2014296
Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies.
PMID: 34577584 PMCID: PMC8468026 DOI: 10.3390/ph14090884